Showing results (921-930 of 3,150) with videos related to

Sort By:
Pageof 315
Neuro-Oncology|June 1, 2010
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivoMotoo Nagane, Saki Shimizu, Eiji Mori, et al.
Neuro-Oncology|June 1, 2010
Evaluation of retinoic acid therapy for OTX2-positive medulloblastomasRenyuan Bai, I-Mei Siu, Betty M Tyler, et al.
Neuro-Oncology|June 1, 2010
A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivoLitian Yu, Patricia A Baxter, Horatiu Voicu, et al.
Neuro-Oncology|June 1, 2010
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastomaSandeep Kunwar, Susan Chang, Manfred Westphal, et al.
Neuro-Oncology|June 1, 2010
Symptoms and problems in the end-of-life phase of high-grade glioma patientsEefje M Sizoo, Lies Braam, Tjeerd J Postma, et al.
Neuro-Oncology|May 13, 2020
Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trialMarianne Schell, Irada Pflüger, Gianluca Brugnara, et al.
Neuro-Oncology|April 28, 2020
A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the ElderlyShervin Tabrizi, Lorenzo Trippa, Daniel Cagney, et al.
Neuro-Oncology|May 10, 2020
Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20CJeanette E Eckel-Passow, Kristen L Drucker, Thomas M Kollmeyer, et al.
Neuro-Oncology|May 10, 2020
HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive markerBrunilde Gril, Debbie Wei, Alexandra S Zimmer, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Pageof 315